Genprex Gene Therapy Shows Strong Preclinical Efficacy in Lung Cancer

AUSTIN, TX — October 23, 2025 — Genprex, Inc., a clinical-stage gene therapy company, announced that its lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), demonstrated significant tumor shrinkage in preclinical studies for ALK-EML4 positive non-small cell lung cancer (NSCLC). The positive data, generated by Genprex’s research collaborators, will be presented at the upcoming 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics, taking place this week in Boston.

Promising Activity as Single Agent and in Combination

The preclinical study explored the therapeutic potential of REQORSA in the challenging ALK Positive NSCLC setting.

• Tumor Shrinkage: Researchers found that REQORSA, administered alone or in combination with the tyrosine kinase inhibitor alectinib, was able to shrink tumors by 79 percent.
• Therapeutic Potential: These results suggest REQORSA may be effective both as a single agent and as an “ideal companion drug” to enhance the effects of existing treatments for patients with advanced disease.

Ryan Confer, President and Chief Executive Officer at Genprex, stated, “We are delighted to have our academic partners present this compelling preclinical evidence that supports the therapeutic use of REQORSA in ALK Positive NSCLC. These data support a pathway for a potential future clinical trial for REQORSA.”

About Reqorsa Gene Therapy

REQORSA (quaratusugene ozeplasmid) is an investigational gene therapy designed to be highly selective for cancer cells.

• Mechanism: It consists of a plasmid containing the TUSC2 gene encapsulated in positively charged non-viral lipid-based nanoparticles (the Company’s Oncoprex Delivery System).
• Targeting: REQORSA is administered intravenously and specifically targets negatively charged cancer cells, with laboratory studies at MD Anderson showing TUSC2 uptake in tumor cells was 10 to 33 times the uptake in normal cells. The therapy is designed to deliver the functioning TUSC2 gene while minimizing uptake by normal tissue.